Literature DB >> 26511438

Neuroprotective activity of stiripentol with a possible involvement of voltage-dependent calcium and sodium channels.

Marc Verleye1, Dorothée Buttigieg2, Rémy Steinschneider2.   

Abstract

A growing body of data has shown that recurrent epileptic seizures may be caused by an excessive release of the excitatory neurotransmitter glutamate in the brain. Glutamatergic overstimulation results in massive neuronal influxes of calcium and sodium through N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, and kainic acid glutamate subtype receptors and also through voltage-gated calcium and sodium channels. These persistent and abnormal sodium and calcium entry points have deleterious consequences (neurotoxicity) for neuronal function. The therapeutic value of an antiepileptic drug would include not only control of seizure activity but also protection of neuronal tissue. The present study examines the in vitro neuroprotective effects of stiripentol, an antiepileptic compound with γ-aminobutyric acidergic properties, on neuronal-astroglial cultures from rat cerebral cortex exposed to oxygen-glucose deprivation (OGD) or to glutamate (40 µM for 20 min), two in vitro models of brain injury. In addition, the affinity of stiripentol for the different glutamate receptor subtypes and the interaction with the cell influx of Na(+) and of Ca(2+) enhanced by veratridine and NMDA, respectively, are assessed. Stiripentol (10-100 µM) included in the culture medium during OGD or with glutamate significantly increased the number of surviving neurons relative to controls. Stiripentol displayed no binding affinity for different subtypes of glutamate receptors (IC50  >100 µM) but significantly blocked the entry of Na(+) and Ca(2+) activated by veratridine and NMDA, respectively. These results suggest that Na(+) and Ca(2+) channels could contribute to the neuroprotective properties of sitiripentol.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  L-glutamate; neuronal-astroglial culture; neuroprotection; oxygen-glucose deprivation; stiripentol; voltage-gated sodium and calcium channels

Mesh:

Substances:

Year:  2015        PMID: 26511438     DOI: 10.1002/jnr.23688

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  8 in total

Review 1.  Treatment Strategies for Dravet Syndrome.

Authors:  Kelly G Knupp; Elaine C Wirrell
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

Review 2.  Pharmacotherapy for Dravet Syndrome.

Authors:  Adam Wallace; Elaine Wirrell; Daniel L Kenney-Jung
Journal:  Paediatr Drugs       Date:  2016-06       Impact factor: 3.022

Review 3.  Stiripentol in the Management of Epilepsy.

Authors:  Katherine C Nickels; Elaine C Wirrell
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

4.  Therapeutic effects of stiripentol against ischemia-reperfusion injury in gerbils focusing on cognitive deficit, neuronal death, astrocyte damage and blood brain barrier leakage in the hippocampus.

Authors:  Myoung Cheol Shin; Tae-Kyeong Lee; Jae-Chul Lee; Hyung Il Kim; Chan Woo Park; Jun Hwi Cho; Dae Won Kim; Ji Hyeon Ahn; Moo-Ho Won; Choong-Hyun Lee
Journal:  Korean J Physiol Pharmacol       Date:  2022-01-01       Impact factor: 2.016

5.  Stiripentol inhibits spike-and-wave discharges in animal models of absence seizures: A new mechanism of action involving T-type calcium channels.

Authors:  Veronique Riban; Isabelle Heulard; Lucie Reversat; Hakim Si Hocine; Marc Verleye
Journal:  Epilepsia       Date:  2022-03-09       Impact factor: 6.740

6.  Efficacy and Safety of Long-Term Treatment with Stiripentol in Children and Adults with Drug-Resistant Epilepsies: A Retrospective Cohort Study of 196 Patients.

Authors:  Simona Balestrini; Viola Doccini; Alessandra Boncristiano; Matteo Lenge; Salvatore De Masi; Renzo Guerrini
Journal:  Drugs Real World Outcomes       Date:  2022-06-09

7.  Antiepileptic Stiripentol May Influence Bones.

Authors:  Agnieszka Matuszewska; Beata Nowak; Anna Nikodem; Anna Merwid-Ląd; Benita Wiatrak; Tomasz Tomkalski; Diana Jędrzejuk; Ewa Szeląg; Tomasz Sozański; Maciej Danielewski; Paulina Jawień; Ireneusz Ceremuga; Marta Szandruk-Bender; Marek Bolanowski; Jarosław Filipiak; Adam Szeląg
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

8.  P2Y6 and P2X7 Receptor Antagonism Exerts Neuroprotective/ Neuroregenerative Effects in an Animal Model of Parkinson's Disease.

Authors:  Ágatha Oliveira-Giacomelli; Carolina M Albino; Hellio Danny Nóbrega de Souza; Juliana Corrêa-Velloso; Ana Paula de Jesus Santos; Juliana Baranova; Henning Ulrich
Journal:  Front Cell Neurosci       Date:  2019-11-08       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.